




SCOLR Pharma



General Corporate Presentation June 9th, 2011

**CDT[®] is a registered trademark of SCOLR Pharma, Inc.
SCOLR & CDT logo and design are trademarks of SCOLR Pharma, Inc.**



Forward-Looking Statements

- This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements of our expectations concerning future strategies, product development programs, revenue opportunities, and expectations about expense reimbursement, future profitability, 2011 financial projections, product approval requirements and timelines. These statements represent management's present expectations of future events that involve significant risks and uncertainties and are subject to a number of important factors that could cause actual results to differ materially from those described in the forward-looking statements.
- Please refer to the risk factors and other cautionary language included in our reports and other filings with the Securities and Exchange Commission and available on our website.
- We assume no obligation to update these forward-looking statements.



Vision:

- **Build shareholder value**
- **By profitably marketing**
- **OTC healthcare & nutritional products**
- **To consumers**
- **Utilizing SCOLR's proprietary extended release technology**



A New Direction

- 2010 focused business activity to consumer market for OTC healthcare & nutritionals
 - Secured outsourced sales & distribution support for consumer market
 - Secured business development support for strategic alliances in the global OTC marketplace
- Abandoned in-house product development / licensing strategy proven to be unsustainable



→ SCOLR's exclusive patented technology


- Consistent release rates over 12 to 24 hours
- Proven in 19 clinical trials
- Over 35 US and International patents extending to (2023 +)
- Reduces dosing for consumers / improved compliance
- New margin opportunity for retailers

SCOLR's Unique Competitive Advantage & A Barrier to Entry



Controlled Delivery Technology

Steady concentration of active ingredients available for absorption into bloodstream





Core Product Pipeline:

- Extended release nutritional supplements
 - 17 unique products
 - New innovation in category
- Extended release ibuprofen tablet
 - Global opportunity
 - Patent protection to (2025) & regulatory exclusivity
 - Nuprin[®] brand name (instant consumer awareness)



Addressable Market for Ibuprofen based products:




Table provided by NHC, Source: DB6 2010 (MSP) *CAGR refers to period 2005- 2009 in all instances unless stated otherwise

2009 US Analgesic Market					
Rank	Brand	Active Ingredients	\$mn	CAGR	MS
1	Tylenol (J&J)	Acetaminophen	778.5	+0.1%	27.4%
2	Advil (Pfizer)	Ibuprofen	452.1	+3.6%	15.9%
3	Motrin (J&J)	Ibuprofen	212.1	+3.1%	7.5%
4	Aleve (Bayer)	Naproxen	192.8	+10.5%	6.8%
5	Aspirin (Bayer)	Aspirin	190.1	+2.3%	6.7%
6	Excedrin (Novartis)	Aspirin, Acetaminophen	175.7	+2.2%	6.2%

OTC Analgesic Market:


- 5% CAGR over last 5 years
- 70% of market top 6 brands
- Ibuprofen 23% of market
- Ibuprofen 2nd fastest growth segment
- No significant consumer news since 1994 (Aleve introduced)
- Dominated by global Pharma



ER Ibuprofen Product Attributes:

- 600 mg 12 hour extended release tablet
 - 1 SCOLR ER tablet = 3 IR
 - Fast pain relief - less than 1 hour
 - Single dose lasts 12 hours

12 Hours of Pain Relief



Others = 3 doses

SCOLR = 1 dose



Immediate Market Opportunity: Nutritionals

- Retail market \$4.4 B today
- Forecasted to \$13.0 B by 2014
- CAGR (5.5%)

*Source: IRI and Nielsen data 2010 *CAGR refers to period 2005- 2009, calculated from Market Research.com 2010*

- Top 10 Retailers - 81% of US retail market
 - Advanced discussions with 4 major retailers
Representing 60% of US retail market
- SCOLR products 1st ER in nutritionals
- Improved retail sales & profit opportunity
- PL strategy minimizes marketing investment





17 Exclusive 12/24 Hour CDT Formulas: Take existing relationships - DIRECT





SCOLR Products Nutritional

Provide consumers:

- New improved performance
- Convenience
- Value

Provide retailers:

- New sales growth opportunity
- Improved profitability
- Better shelf space management



Promising, Positive, Profitable Momentum

- Proprietary Technology
- Going direct & capitalizing on existing customer relationships
- Emerson Health Care
 - Represent \$1.15 billion in retail sales
 - Strong retail relationships
 - Cost efficient distribution & logistic services
- Nicholas Hall
 - Recognized global business consultant
 - Relationships with leading global consumer companies
- Over \$1 M in annualized cost reductions



Balance Sheet and Capital Structure

December 31, 2010

(In Thousands)

Cash and cash equivalents

\$ 1,891

Working Capital

1,966

Total Assets

\$ 3,858

Total Debt

-

(In Millions)

Common Shares Outstanding

49.8

Fully - Diluted Shares

57.9



Company Management

Stephen J. Turner, *President & Chief Executive Officer*

- **Joined SCOLR in 1999**
- **Served as Chief Technology Officer in charge of R&D and Operations since 2003 until being appointed President and CEO in August 2009**
- **Built SCOLR's R&D, Intellectual Property and Information Technology Functions**

Richard M. Levy, *Executive Vice President & Chief Financial Officer*

- **Joined SCOLR in 2005**
- **Extensive experience in acquisitions and divestures**
- **Held several executive level positions with domestic and international companies, including CFO of Bank of America's International Private Banking Division, Bank of America Australia, and CFO at Community Trust Bank, Kentucky**



Strong Board

Significant depth of experience across a broad array of business disciplines

Executive management in:

- **Consumer Products**
- **Financial**
- **Medical**
- **Regulatory**